BAF60c and abdominal aortic aneurysm
BAF60c 和腹主动脉瘤
基本信息
- 批准号:10297104
- 负责人:
- 金额:$ 54.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:AbdomenAbdominal Aortic AneurysmAddressAffectAgeAneurysmAngiotensin IIAortaApoptosisAtherosclerosisAttentionAttenuatedAutomobile DrivingBlood VesselsCardiovascular systemCatalytic DomainCathepsinsCellsCellular biologyChIP-seqChromatinChromatin Remodeling FactorChromatin StructureCo-ImmunoprecipitationsComplementComplexContractile ProteinsDNADataDevelopmentDiabetes MellitusElastasesEnergy MetabolismEnvironmentEpigenetic ProcessExtracellular Matrix DegradationFamilyFamily memberFunctional disorderGene ExpressionGenesHeartHomeostasisHumanHyperlipidemiaHypertensionIn VitroIncidenceIndividualInflammationInflammatoryKnock-in MouseKnock-outKnockout MiceLigandsLinkLipidsLoxP-flanked alleleMMP9 geneMedialMediatingMedicalMetabolicMolecularMusOperative Surgical ProceduresOutcomePathogenesisPathologicPathologyPathway interactionsPatientsPharmaceutical PreparationsPharmacologic SubstancePharmacotherapyPhenotypePlayPrevalencePrimary PreventionProcessPromoter RegionsReceptor SignalingRegulationReportingRisk FactorsRoleRuptureSMARCA4 geneSamplingSchemeSex DifferencesSmokingSmooth Muscle MyocytesStainsStimulusSucroseTherapeuticThoracic Aortic AneurysmTissue SampleTissuesTransducersTransgenic MiceTranslatingVascular Smooth MuscleViral VectorWorkbasebrahmachromatin remodelingdifferential expressiongenetic associationgenomic locusgranulocytehigh riskin vivoin vivo Modelinsightknock-downloss of functionmalemembermortalitymortality riskmouse modelnovelnovel therapeuticsp65preventpromoterprotein expressionrecruitrepairedresponsesextherapeutic targettranscription factortranscriptome sequencingvascular inflammation
项目摘要
PROJECT SUMMARY/ABSTRACT
Abdominal Aortic Aneurysm (AAA) is a primary medical concern due to the increasing prevalence and high
mortality rate upon rupture. Although vascular inflammation, extracellular matrix (ECM) degradation, and
subsequent vascular smooth muscle cells (VSMCs) apoptosis are pathologic features and drivers of AAA,
efforts to manipulate these processes did not yet result in any effective drug therapies beyond primary
prevention, creating an urgent need for new drug-based therapeutic strategies. This will be facilitated by a
deeper and comprehensive understanding of the molecular and cellular mechanisms driving onset,
progression, and outcomes of AAA. Chromatin remodeling altering gene expression has been linked to most
pathophysiologic conditions, including atherosclerosis and diabetes, but its role in AAA remains largely
unknown. The BAF60 family comprises three mutually exclusive subunits of the SWItch/Sucrose Non-
Fermentable (SWI/SNF) chromatin remodeling complex. Of relevance to the cardiovascular field, they play
essential roles in controlling lipid homeostasis, energy metabolism (BAF60a), granulocyte (BAF60b) and heart
(BAF60c) development. We found that BAF60a, b and c are differentially expressed in human and mouse AAA
tissues, suggesting a potential role of the BAF60 subunits in VSMC biology and the development of AAA. We
recently reported that loss of BAF60a in VSMCs prevents experimental AAA by reducing vascular inflammation
and ECM degradation in mice. Remarkably, BAF60c is the most abundant BAF60 subunit expressed in VSMC.
Our preliminary data show that BAF60c is downregulated in the abdominal aortic aneurysmal tissue in both
humans and mice. VSMC BAF60c knockout significantly aggravates elastase-induced AAA, and knockdown of
BAF60c in human aortic smooth muscle cells reduced the SMC contractile protein expression and increased
inflammatory genes and MMP9 expression. We hypothesize that VSMC-specific BAF60c attenuates AAA
development by maintaining the VSMC contractile phenotype, and inhibiting vascular inflammation and ECM
degradation. Using gain- and loss-of-function in HASMCs in vitro, AAA-relevant stimuli, our unique VSMC-
specific BAF60c knockout and transgenic mice, two established murine AAA models in vivo, and an integrated
workflow, we will (Aim 1) Demonstrate that VSMC-specific BAF60c attenuates AAA formation with attention to
altered cellular profiles and intercellular cross-talk by scRNAseq and provide proof-of-concept for therapeutic
targeting and (Aim 2) Determine the protective mechanisms of BAF60c in VSMC homeostasis in vitro using
relevant stimuli and RNAseq, ChIP-seq and co-immunoprecipitation. This work will provide unique mechanistic
insights on how various and varying risk factors translate into VSMC dysfunction leading to AAA and provide
the basis for developing novel therapies for AAA.
项目摘要/摘要
腹主动脉瘤(AAA)是一种主要的医学问题,因为它的发病率和高发病率
破裂时的死亡率。尽管血管炎症、细胞外基质(ECM)降解以及
随后的血管平滑肌细胞(VSMCs)凋亡是AAA的病理特征和驱动因素。
操纵这些过程的努力尚未产生除初级治疗外的任何有效药物治疗
预防,迫切需要新的基于药物的治疗策略。这将由一个
更深入和全面地了解推动发病的分子和细胞机制,
AAA的进展和转归。染色质重塑改变基因表达与大多数
病理生理条件,包括动脉粥样硬化和糖尿病,但其在AAA中的作用仍很大
未知。BAF60家族由三个互不相容的开关/蔗糖非-
可发酵(SWI/SNF)染色质重塑复合体。与心血管领域相关的,他们发挥作用
在控制脂平衡、能量代谢(BAF60a)、粒细胞(BAF60b)和心脏中的重要作用
(BAF60c)发展。我们发现BAF60a、b和c在人和小鼠的AAA中有差异表达
提示BAF60亚基在VSMC生物学和AAA的发展中具有潜在的作用。我们
最近报道,VSMCs中BAF60a的缺失可通过减轻血管炎症来预防实验性AAA
和ECM在小鼠体内的降解。值得注意的是,BAF60c是VSMC中表达最丰富的BAF60亚基。
我们的初步数据显示BAF60c在两组腹主动脉瘤组织中表达下调。
人类和老鼠。VSMC BAF60c基因敲除显著加重弹性蛋白酶诱导的AAA,并下调
BAF60c在人主动脉平滑肌细胞中表达降低,SMC收缩蛋白表达增加
炎症基因和MMP9的表达。我们假设VSMC特异性的BAF60c可以减弱AAA
维持VSMC收缩表型,抑制血管炎症和细胞外基质的发展
退化。利用体外培养的HASMC的增减功能,AAA相关的刺激,我们独特的VSMC-
特异性BAF60c基因敲除和转基因小鼠,两种已建立的体内小鼠AAA模型,以及整合的
工作流程,我们将(目标1)演示VSMC特异性BAF60c通过关注以下几个方面来减少AAA的形成
通过scRNAseq改变细胞轮廓和细胞间串扰,并为治疗提供概念验证
靶向性研究及BAF60c对VSMC动态平衡的保护机制
相关刺激与RNASEQ、CHIP-SEQ及免疫共沉淀。这项工作将提供独特的机械性
洞察各种不同的风险因素如何转化为VSMC功能障碍导致AAA并提供
为开发治疗腹主动脉瘤的新疗法奠定基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jifeng Zhang其他文献
Jifeng Zhang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jifeng Zhang', 18)}}的其他基金
Novel methods to improve nuclease mediated homologous recombination, Administrative suppl
改进核酸酶介导的同源重组的新方法,行政补充
- 批准号:
10640401 - 财政年份:2022
- 资助金额:
$ 54.38万 - 项目类别:
Kruppel-like factor 11 (KLF11) and atherosclerosis
Kruppel 样因子 11 (KLF11) 和动脉粥样硬化
- 批准号:
9924279 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改善核酸酶介导的同源重组的新方法
- 批准号:
10615626 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改进核酸酶介导的同源重组的新方法
- 批准号:
9345608 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
Novel methods to improve nuclease mediated homologous recombination
改善核酸酶介导的同源重组的新方法
- 批准号:
10383251 - 财政年份:2017
- 资助金额:
$ 54.38万 - 项目类别:
相似海外基金
Establishment of human abdominal aortic aneurysm wall strength prediction model using Ex Vivo Superparamagnetic Iron Oxide–Enhanced Magnetic Resonance Imaging
利用Ex Vivo超顺磁性氧化铁建立人体腹主动脉瘤壁强度预测模型
- 批准号:
23K08226 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Extracellular Vesicle Delivery System for Treatment of Abdominal Aortic Aneurysm
细胞外囊泡递送系统治疗腹主动脉瘤
- 批准号:
10751123 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
Vascular smooth muscle cell ferroptosis and abdominal aortic aneurysm
血管平滑肌细胞铁死亡与腹主动脉瘤
- 批准号:
10733477 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
I-Corps: A Clinical Decision Support Tool to Manage Abdominal Aortic Aneurysm Patients
I-Corps:管理腹主动脉瘤患者的临床决策支持工具
- 批准号:
2318665 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
Standard Grant
Atherosclerosis drives arterial damage and abdominal aortic aneurysm formation and rupture
动脉粥样硬化导致动脉损伤和腹主动脉瘤形成和破裂
- 批准号:
483212 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
Operating Grants
Impact of PCSK9 inhibition on abdominal aortic aneurysm pathobiology and growth
PCSK9 抑制对腹主动脉瘤病理学和生长的影响
- 批准号:
10566800 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
Development of phospholipid-based nanotherapeutics for treating abdominal aortic aneurysm
开发基于磷脂的纳米疗法治疗腹主动脉瘤
- 批准号:
10749980 - 财政年份:2023
- 资助金额:
$ 54.38万 - 项目类别:
The Role of Amino Acid Starvation Response Kinase GCN2 in Abdominal Aortic Aneurysm
氨基酸饥饿反应激酶 GCN2 在腹主动脉瘤中的作用
- 批准号:
10584543 - 财政年份:2022
- 资助金额:
$ 54.38万 - 项目类别:
Atherosclerotic process drives arterial damage, abdominal aortic aneurysm formation, and rupture
动脉粥样硬化过程导致动脉损伤、腹主动脉瘤形成和破裂
- 批准号:
477264 - 财政年份:2022
- 资助金额:
$ 54.38万 - 项目类别:
Operating Grants
Endovascular Orifice Detection (EOrD) Device for in situ Fenestration of Abdominal Aortic Aneurysm
用于腹主动脉瘤原位开窗的血管内孔口检测 (EOrD) 装置
- 批准号:
10453104 - 财政年份:2022
- 资助金额:
$ 54.38万 - 项目类别:














{{item.name}}会员




